STAT+: Pharmalittle: We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
Why it matters: Novo Nordisk's struggles and aggressive pricing signal a shifting landscape in the competitive obesity drug market.
- Novo Nordisk chairman Lars Rebien Sorensen will face investors for the first time since a boardroom coup, amid a 45% stock decline and recent failures, including losing an obesity startup bid to Pfizer and issuing a gloomy forecast (Bloomberg News).
- Novo Nordisk is reducing Wegovy prices in South Africa for the second time, with the lowest dose dropping 60% and the highest 27%, to compete with Eli Lilly and correct initial pricing (Reuters).
- Eli Lilly's market value grew by a fifth over the same period, briefly making it the world's first $1 trillion drugmaker, highlighting Novo Nordisk's struggles (Bloomberg News).
- Denali Therapeutics and Corcept Therapeutics have secured FDA approvals for their respective drugs, indicating broader activity in the pharmaceutical industry (STAT News).
Novo Nordisk faces investor scrutiny over recent missteps and a significant stock drop, even as its rival Eli Lilly's market value surged. The company is also aggressively cutting prices for its weight-loss drug Wegovy in South Africa, citing fierce competition and initial pricing misjudgments, a move that could impact global market strategies.
